Abstract |
The clinical efficacy of botulinum toxin type A was studied in patients with blepharospasm. Clinical symptoms were evaluated using the Jankovic rating scale. To measure dose response, we used a recently developed device to measure eyelid muscle force. The results showed significant improvement (P = 0.0000) in the Jankovic rating scale scores in all dose groups. The number of patients with marked improvement (6-point decrease or more in the total Jankovic rating scale score) increased with higher dose injections. After injections of 0.50, 1.25, or 2.50 U/site, 6 sites/eye, the eyelid muscle force decreased by 33.2 +/- 28.1%, 41.7 +/- 25.1%, or 69.6 +/- 5.0%, respectively. The decrease of eyelid muscle force showed a significant dose response (P = 0.0254). The mean duration of effect was 12.9 weeks in patients after dose injections of 1.25 U/site, which was significantly longer (P = 0.0205) than the 9.6 weeks in patients after dose injections of 0.50 U/site. No severe adverse effects were observed. We concluded that injections of botulinum toxin type A at an initial dose of 1.25 U/site are a safe and effective treatment for blepharospasm.
|
Authors | H Iwashige, Y Nemeto, H Takahashi, T Maruo |
Journal | Japanese journal of ophthalmology
(Jpn J Ophthalmol)
Vol. 39
Issue 4
Pg. 424-31
( 1995)
ISSN: 0021-5155 [Print] Japan |
PMID | 8926651
(Publication Type: Journal Article)
|
Chemical References |
- Neurotoxins
- Botulinum Toxins
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Blepharospasm
(drug therapy, physiopathology)
- Botulinum Toxins
(therapeutic use)
- Dose-Response Relationship, Drug
- Eyelids
(physiopathology)
- Female
- Humans
- Male
- Neurotoxins
(therapeutic use)
- Severity of Illness Index
- Treatment Outcome
|